Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Sanofi - American Depositary Shares
(NQ:
SNY
)
45.99
+0.85 (+1.88%)
Streaming Delayed Price
Updated: 10:20 AM EDT, Mar 25, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sanofi - American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
41
42
Next >
AI Revolutionizes Drug Shelf-Life: Optimized Stability Models Promise Safer, More Effective Medicines
November 14, 2025
The pharmaceutical industry is on the cusp of a profound transformation, driven by the integration of data science and Artificial Intelligence (AI) into drug formulation stability models. This...
Via
TokenRing AI
Topics
Artificial Intelligence
Economy
Product Recall
Biopharma Boom: M&A Frenzy, AI Revolution, and GLP-1 Gold Rush Drive Robust Growth in 2025
November 14, 2025
The pharmaceutical and biotechnology sectors are experiencing a period of significant dynamism and robust growth as of November 2025, fueled by a confluence of scientific advancements, a resurgence in...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Intellectual Property
Why Roche Holding Stock Popped Today
↗
November 10, 2025
Roche is great at developing drugs -- but is its stock a great buy?
Via
The Motley Fool
TG Therapeutics Crumbles After Roche Unveils Its 'Unprecedented' Test Results
↗
November 10, 2025
Roche presented "unprecedented" test results for its multiple sclerosis treatment, putting pressure on rival TG Therapeutics.
Via
Investor's Business Daily
Merck Takes On Amgen, Regeneron, Lowering Stubbornly High Cholesterol By 60%
↗
November 08, 2025
Merck said Saturday its new pill — a possible rival to Regeneron and Amgen — lowered high cholesterol by almost 60%.
Via
Investor's Business Daily
AI Achieves Atomic Precision in Antibody Design: A New Era for Drug Discovery Dawns
November 05, 2025
Seattle, WA – November 5, 2025 – In a monumental leap for biotechnology and artificial intelligence, Nobel Laureate David Baker’s lab at the University of Washington’s Institute for Protein Design...
Via
TokenRing AI
Topics
Artificial Intelligence
Intellectual Property
AI Unleashes a New Era in Cell and Gene Therapy: A Quarter Century Update Reveals Transformative Potential
November 04, 2025
The burgeoning fields of cell and gene therapy (CGT) are on the cusp of a profound revolution, driven by the relentless advancements in artificial intelligence. This transformative impact was a central...
Via
TokenRing AI
Topics
Artificial Intelligence
AI Unleashes a New Era: Biopharma’s Accelerated Revolution and the Rise of TechBio
November 01, 2025
The biopharmaceutical industry is undergoing an immediate and profound transformation, as Artificial Intelligence (AI) rapidly compresses timelines, drastically reduces costs, and significantly...
Via
TokenRing AI
Topics
Animal Testing
Artificial Intelligence
Economy
Regeneron's Q3 Earnings Outperform Expectations With Dupixent Strength Balancing Eylea Weakness
↗
October 28, 2025
Regeneron posts Q3 earnings of $11.83 per share, topping estimates as Dupixent profits lift results despite weaker Eylea sales.
Via
Benzinga
UPDATE - Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey
October 27, 2025
Expanded 10-plus-year collaboration will leverage Medidata Experiences with the goal of streamlining clinical processes and data, enhancing patient care
From
Medidata Solutions, Inc.
Via
GlobeNewswire
Sanofi Soars as Dupixent Sales Near €5 Billion Amidst Intensifying Trump Drug Pricing Negotiations
October 24, 2025
Paris, France – October 24, 2025 – Pharmaceutical giant Sanofi (EURONEXT: SAN, NASDAQ: SNY) saw its shares climb today following the announcement of stellar third-quarter 2025 financial results,...
Via
MarketMinute
Topics
Government
World Trade
Dupixent Pushes Sanofi's Quarterly Sales Past $14.5 Billion Mark
↗
October 24, 2025
Sanofi Q3 sales beat estimates on strong Dupixent and new drug demand; reaffirms 2025 outlook with double-digit EPS growth expected.
Via
Benzinga
Topics
Earnings
Sanofi Jumps As Third-Quarter Dupixent Sales Near $5 Billion
↗
October 24, 2025
Sanofi stock jumped early Friday on better-than-expected quarterly sales.
Via
Investor's Business Daily
Earnings Scheduled For October 24, 2025
↗
October 24, 2025
Via
Benzinga
Oil Stocks Rally On Trump's Russia Sanctions: What's Moving Markets Thursday?
↗
October 23, 2025
Energy markets dominated headlines Thursday as a fresh wave of U.S. sanctions targeting Russia's oil giants sparked a sharp rebound in crude prices and lifted energy shares.
Via
Benzinga
Topics
Government
Examining the Future: Sanofi's Earnings Outlook
↗
October 23, 2025
Via
Benzinga
Sanofi Deepens Partnership with Medidata to Expedite the Development of New Therapies with an Improved Patient Journey
October 23, 2025
Expanded 10-plus-year collaboration will leverage Medidata Experiences, enabling Sanofi to streamline operations, refine data quality, and enhance patient care
From
Medidata Solutions, Inc.
Via
GlobeNewswire
Sanofi Drug Shows Superior Efficacy In Genetic Disease Compared To Current Standard Therapy
↗
October 22, 2025
Sanofi revealed topline data from the ElevAATe phase 2 study of efdoralprin alfa (SAR447537, formerly known as INBRX-101).
Via
Benzinga
Nurix Therapeutics (NASDAQ: NRIX) Stock Soars as Pivotal Phase 2 Study for Bexobrutideg Ignites Investor Confidence
October 22, 2025
San Francisco, CA – October 22, 2025 – Nurix Therapeutics (NASDAQ: NRIX) has captured significant market attention, with its stock experiencing a notable surge following the announcement of the...
Via
MarketMinute
Sanofi's Rezurock Approval Stumbles In EU For Chronic Graft-Vs-Host Disease
↗
October 17, 2025
CHMP rejects Sanofi's Rezurock for chronic GVHD in the EU, while approving Wayrilz for ITP, highlighting mixed outcomes for new treatments.
Via
Benzinga
FDA Unveils First Experimental Drugs Under Fast-Track Voucher Plan To Cut Drug Review Times
↗
October 17, 2025
The FDA launched a new voucher program to fast-track reviews, naming nine experimental drugs for cancer, diabetes, addiction, and other conditions.
Via
Benzinga
Revolution Medicines, Disc Medicine, Regeneron Stocks Jump After-Hours As FDA Fast-Tracks 9 Drugs Under New Review Program
↗
October 17, 2025
The FDA’s new National Priority Voucher pilot helps with faster drug reviews, cutting timelines from nearly a year to weeks.
Via
Stocktwits
Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential
↗
October 14, 2025
Shah Capital urges Novavax to consider a sale after poor COVID-19 vaccine rollout, highlighting the potential value of at least $5 billion.
Via
Benzinga
Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out
↗
October 09, 2025
The small biotech company is looking to take on Regeneron and Sanofi's blockbuster, Dupixent.
Via
Investor's Business Daily
Sanofi AlphaMedix Study Hits Key Milestones In Phase 2 Study
↗
October 08, 2025
Sanofi reports that its AlphaMedix phase 2 trial showed strong efficacy and survival benefits in gastroenteropancreatic neuroendocrine tumors.
Via
Benzinga
Here's Why Nektar Therapeutics Stock Rocketed 90.6% Higher in September
↗
October 05, 2025
Results of the Resolve-AD trial with rezpegaldesleukin were better than expected.
Via
The Motley Fool
AI Revolutionizes Pharma: Market Soars Towards $65 Billion by 2033, Promising a New Era of Medicine
October 02, 2025
The pharmaceutical industry is on the cusp of a profound transformation, driven by the accelerating integration of Artificial Intelligence (AI). Projections indicate that the global AI in...
Via
TokenRing AI
Topics
Artificial Intelligence
Economy
Thermo Fisher Scientific Soars on Strategic Wins, Market Optimism
October 01, 2025
Thermo Fisher Scientific Inc. (NYSE: TMO) experienced a robust surge in its stock value today, October 1, 2025, climbing an impressive 9.79% as market optimism swelled around a series of recent...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Government
Novavax Amends Deal With Sanofi, Broadens Partnership
↗
September 30, 2025
The amendment of the agreement allows for the use of Matrix-M in early-stage development of Sanofi's pandemic influenza vaccine candidate.
Via
Stocktwits
GSK Leaps Into Buy Zone On Surprise Departure Of CEO Emma Walmsley
↗
September 29, 2025
Shares had broke out earlier this month, but have floundered at the lower boundary of the chart pattern.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
8
9
...
41
42
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
